Novo Nordisk's Bone-Health Readout and Buyback Milestone Cap a Busy November
Published on 11/20/2026 at 13:41 | Editorial boerse-global.deNovo Nordisk used the ObesityWeek stage on Monday to present a post-hoc analysis of the REDEFINE 1 trial focused on bone health during weight loss. According to the company, bone mineral density after 68 weeks remained within the normal range for age and sex. The study was not designed to determine whether the risk of fractures declines, leaving that question unanswered.
Early Responders Pull Ahead on the Scale
That same post-hoc look at REDEFINE 1, released on Sunday, showed that 67.8% of patients treated with CagriSema responded early to the therapy. Among these early responders, observed weight loss through week 68 averaged 25.4%. Novo Nordisk describes the analysis as exploratory and intended for hypothesis generation.
CagriSema's Phase 3 Numbers
On November 14, the Danish drugmaker published results from the Phase 3 REDEFINE 9 study of the investigational drug CagriSema. Assuming continuous treatment, estimated mean weight loss at 68 weeks came in at 20.7% for the higher of the two doses tested and 21.0% for the lower. The placebo arm posted an estimated 2.0% reduction under the same assumption. A separate filing covers a 2.4 mg dose of each active ingredient, with a US decision anticipated in the fourth quarter of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buyback Tally Reaches DKK 12.1 Billion
Novo Nordisk also disclosed on Monday the repurchase of 1.13 million B shares for roughly DKK 310 million. Since February 4, the company has bought back approximately 43.7 million B shares for a total of around DKK 12.1 billion.
Brussels Clears FREHEMGO
The European Commission granted marketing authorization for FREHEMGO on November 13 for routine prophylaxis in hemophilia A. The approval covers adults and children, with or without inhibitors. Novo Nordisk expects the first European launches next year.
Etavopivat Filings Land on Both Sides of the Atlantic
Two days earlier, on November 12, Novo Nordisk submitted marketing applications to the US Food and Drug Administration and the European Medicines Agency for etavopivat. The investigational therapy is intended for people aged twelve and older with sickle cell disease. The company anticipates an FDA decision on the US application in 2027.
Ad
Novo Nordisk Stock: New Analysis - 20 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
